1-2 of 2
Jennifer Smith, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Farhad Ravandi, MD, Ellen K. Ritchie, MD, Hamid Sayar, MD, Jeffrey E. Lancet, MD, Michael Craig, MD, Norbert Vey, MD PhD, Stephen A. Strickland, Gary J. Schiller, MD, Elias J. Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD PhD, Christian Recher, MD PhD, Virginia M. Klimek, MD, Jorge E. Cortes, MD, Gail J. Roboz, Adam R. Craig, MD PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Hagop M. Kantarjian, MD, Robert K. Stuart, MD
Journal: Blood
Blood (2016) 128 (22): 903.
https://doi.org/10.1182/blood.V128.22.903.903
Published: 2016
Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Farhad Ravandi, MD, Ellen Ritchie, MD, Hamid Sayar, MD, Jeffrey Lancet, MD, Michael D. Craig, MD, Norbert Vey, MD, Stephen A. Strickland, MD, Gary Schiller, MD, Elias Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD, Christian Recher, MD, Virginia M. Klimek, MD, Jorge Cortes, MD, Eric J. Feldman, MD, Adam R. Craig, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Gary Acton, MD, Cyrus Mehta, PhD, Hagop M. Kantarjian, MD, Robert K Stuart, MD
Journal: Blood
Blood (2014) 124 (21): LBA-6.
https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6
Published: 2014